June 2016, Vol. 106, No. 6 care facilities. The unit has approximately 2 000 admissions, with an additional 5 500 outpatient visits, per year
Surveillance
Following identification of the first two VRE infections, collaboration between the paediatric oncologists, microbiologists, paediatric infectious diseases physicians, infection control nursing staff and ward nursing staff was instituted to limit further spread by improving infection prevention and control measures. Active surveillance for rectal colonisation with VRE of patients in the ward and discharged patients who had prior contact with the index cases was carried out by means of culture and sensitivity testing using rectal swabs or stool samples. If rectal swabs were negative for VRE at initial screening, a repeat was taken at 1 -2-weekly intervals until three consecutive negative swabs were documented. [5] 
Infection control
Infected patients were isolated in single cubicles until discharged. Contact precautions during patient interaction were instituted for patients, family and staff members. Colonised patients were cohorted until discharged. Medical records were marked to ensure isolation, and re-screening by rectal swab occurred during subsequent admissions. Staff and parents were reeducated regarding correct handwashing tech nique, use of alcohol hand sanitiser and contact precautions.
Microbiological methods
All microbiological and molecular analyses were conducted by the National Health Laboratory Service at Groote Schuur Hospital and the Division of Medical Microbiology, University of Cape Town (UCT), SA. Surveillance specimens were plated directly onto selective media (colistin nalidixic blood agar impregnated with a 30 µg vancomycin disc) and incubated for up to 48 hours. Identification and susceptibility testing of colonies growing within the inhibition zone close to the vancomycin disc were performed using the Vitek 2 GP and AST-P603 cards respectively, with interpretation according to contemporary Clinical Laboratory Standards Institute criteria. [6] Vancomycin minimum inhibitory concentrations (MICs) were determined using the Etest method. [6] MICs ≥32 μg/mL were considered resistant.
Isolates were characterised genotypically with the Hain Genotype Enterococcus line probe assay according to the manufacturer's instructions, or in-house polymerase chain reaction (PCR) assay as described below.
In-house PCR assay for genotyping enterococci
All vancomycin-resistant isolates were screened for the presence of the vancomycin resistance genes vanA, B and C1, 2, 3 with DNA purified using the ZR Fungal/Bacterial DNA MiniPrep kit (Zymo Research, USA) according to the manufacturer's instructions. [7] PCR reactions (25 µL) were carried out using GoTaq Flexi (Promega, USA) with an annealing temperature of 60°C, for 35 cycles, in a GeneAmp 9700 thermocycler. PCR amplicons were visualised by agarose gel electrophoresis and ethidium bromide staining. Amplicons were confirmed with DNA sequence analysis (Inqaba Biotech, SA) and BLASTN (http://blast.ncbi.nlm. nih.gov/Blast) comparisons. [8] 
Pulsed-field gel electrophoresis
Isolates of interest were analysed using pulsed-field gel electrophor esis (PFGE), as described by the Centers for Disease Control and Prevention, with the following changes: cultures were grown on BHI medium, at 37°C, aerobically overnight, and cell densities were standardised to an OD 610nm ≈1.0, using a spectrophotometer (BioDrop, UK). [9] Cells were embedded in a 1.0% SeaKem Gold agarose gel (Lonza, Switzerland) and were digested for 2 hours at 25°C using SmaI (Thermo Scientific, USA) restriction endonuclease and ApaI as a secondary enzyme (2 hours at 37°C). Digested plugs were electrophoresed through a 1.0% SeaKem Gold agarose gel (Lonza, Switzerland) in 0.5% TBE buffer (14 °C), using the Gene Navigator (Amersham Biosciences, UK) at 200 V, with a ramped switching time of 3.5 -23.5 seconds over 18 hours. The resultant gel was visualised using ethidium bromide staining, and the gel image analysed and dendrogram generated using Gel Compare II (BioNumerics v.6.6, Applied-Maths, USA), with an optimisation of 1.0 and a band tolerance of 1.5. The dendrogram was constructed using the pairwise average from the SmaI and ApaI results, with the UPGMA (unweighted pair group method with arithmetical mean) method and branch quality was calculated using the cophenetic correlation. E. faecalis ATCC 51299 was used as a control and for normalisation.
Multilocus sequence typing
Cellular DNA was extracted from selected isolates and PCR was carried out as described above using the conditions described by Homan et al. [10] Amplicons were sequenced bidirectionally (Inqaba Table 1 Biotech, SA) and the consensus sequences uploaded and typed at using an E. faecium multilocus sequence typing (MLST) database.
[11]
Ethical considerations
Ethics approval to perform this study was obtained from the Human Research Ethics Committee, UCT (HREC Ref.
No. 022/2015).
Results

Description of the infection
The ward had 100% occupancy during the months of VRE isolation. All four BSI patients were long-term residents in the unit at the time of the infections and were therefore classified as hospital-acquired infections. Patients 2 and 4 were transferred from a referral hospital outside Cape Town, where VRE had previously been isolated. Neither of these patients was screened prior to their transfer to RCWMCH. The clinical features and underlying risk factors at the time of BSI were similar in all four identified patients ( Table 1 ). Three of the infected patients cultured vancomycin-sensitive E. faecium (VSE) isolates from blood in the week preceding the VRE-BSI. All four were treated with vancomycin in the week prior to the the VRE-BSI, and three had suboptimal vancomycin trough drug levels (≤15 µg/ mL 
Microbiology
All but one isolate obtained (surveillance and infection) was identified as E. faecium, using the Vitek 2 system. The additional isolate obtained on rectal swab was identified as E. faecalis based on vancomycin sensitivity testing. Vancomycin MICs on Etest were ≥256 µg/mL for the four BSI isolates, confirming high-level resistance of E. faecium to vancomycin. [8] Molecular testing PCR analysis detected the vanA gene in all of the VRE isolates obtained from infected patients and all but one of the VRE screening isolates. This isolate tested positive for the vanB gene. PFGE analysis of these isolates showed that there was genetic diversity among the isolates, which was not indicative of an outbreak. There was, however, a high level of genetic relatedness (>85% confidence interval) between some of the strains tested (Fig. 1) . The E. faecalis isolate obtained during the February -March surveillance screening did not undergo any further molecular typing, even though the vanA gene was detected on PCR. Patients 1 and 2, who were considered to be the index cases of a suspected outbreak, had isolates which shared 92.5% homology, indicating a strong possibility of patient-to-patient transmission of the same clone. This result was unusual since the patient 2 isolate in question (No. 
Fig. 1. Dendrogram of isolates obtained during investigation. Shaded bars indicate branch error flags and unshaded values indicate the levels of relatedness. Patients 1 -4 represent the patients with VRE-BSIs. Patients 5, 6 and 8 -11 indicate the patients colonised with VRE (patient 11 in February and March, and patients 5, 6, 8, 9 and 10 in September and October; patient 7 was not a haematology/oncology patient). The specimen types and MLST sequence types are indicated in the last two columns, respectively.
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The second isolate from patient 1 (No. 5), obtained from a blood culture, shared 97.2% homology with the blood culture isolate from patient 3 (No. 30). Isolate No. 30 was faintly positive for the vanA gene on PCR and susceptible to vancomycin. Previous isolates from this patient produced strong positive PCR results and high levels of vancomycin resistance. None of the resistant isolates from patient 3 showed significant homology to the sensitive isolate or to any of the other strains tested (data not shown). The two isolates obtained from blood in patient 1 (Nos 5 and 7), however, shared very little genetic homology. These data indicated the possibility of a rapid rate of strain variation, even within the same patient, in this setting. The two isolates from patient 4 (Nos 39 and 62) shared only 61.1% homology with each other and very low homology with any of the other strains tested.
There were five screening strains, in two clusters, that shared high genetic homology with each other. Cluster 1 (91.4% homology) comprised patients 5, 6 and 7 and cluster 2 (87.8% homology) comprised patients 8 and 9. Patient 7 (No. 14) in cluster 1 was PCRpositive for the vanB gene, but still shared high homology with the other two isolates, which were both vanA-positive. This patient had no prior contact with the haematology/oncology unit. The isolate was obtained from autopsy of the lung tissue and was probably a contaminant and not a comorbidity. Cluster 2 comprised two isolates that were obtained from different patients on the same day. These results indicated the possibility of spread within the hospital.
MLST analysis revealed that the four isolates from patients 1 and 2 (Nos 3, 5, 7 and 13) all shared the same sequence type (ST817). Even though these isolates do not share significant homology in the dendrogram, it strengthens the assumption that these two patients probably had patient-to-patient transmission of the same clone that may have changed over time. The two isolates from patient 4 (Nos 39 and 62) that shared 61.1% homology also shared the same sequence type (ST80). They are single-locus variants of ST817, with a single polymorphism in the adk gene (189G>A).
Infection control
A multidisciplinary approach was instituted to prevent further spread of the organism within the oncology unit. Infection control staff assisted with ensuring that infected patients were isolated and all ward staff members were educated about contact precautions. Colonised patients were cohorted in the multi-bed cubicles for the duration of their hospital stay. Discharged patients were identified to determine who required screening on their next visit.
The ward was closed off to all new admissions until all colonised or infected patients were discharged. Once all colonised or infected patients were discharged, the ward was comprehensively cleaned.
Following the first two cases of VRE-BSI, antibiotic stewardship ward rounds were instituted in the oncology unit, to improve antibiotic management including optimisation of vancomycin dosing. All patients who required transfer from other hospitals to the oncology unit at RCWMCH, where VRE had previously been documented, were screened for VRE by rectal swab prior to transfer.
Discussion
This is the first documented report of VRE infection in children in SA. A prevalence study in SA found 10.9% (20/184) of screening rectal swabs in at-risk patients to be positive for enterococal isolates. [12] This study also showed clonal spread of the vanA and vanB genotypes in different hospitals, as well as persistence of the vanA carrying strain over time. The vanA genotype has been commonly isolated in previous outbreak settings. [2, 3] Even though the PFGE results indicated overall genetic diversity between the isolates analysed, there was a degree of genetic relatedness between specific blood and rectal swab samples on both PFGE and MLST analysis. These results may suggest possible patient-to-patient transfer of VRE or persistence of the organism in the haematology/ oncology unit between the two time periods described. Patient 4 was infected by a molecularly distinct, unrelated isolate, possibly before transfer to RCWMCH at a referral hospital where VRE had previously been isolated. The identified sequence type (ST80) along with ST203 (No. 36) and ST18 (No. 30) have previously been assigned to clonal complexes (CC) CC117, CC78, and CC17, respectively, which are known to form part of the CC17 meroclone. The CC17 meroclone has been described as highly diverse with documented worldwide spread. [13] These data again highlight the high levels of strain variation observed in this setting.
The purpose of screening is to identify carriers during outbreaks, and in non-outbreak settings to prevent transmission, especially to vulnerable patient groups. [14] Active screening outside outbreak settings can be a costly exercise and especially difficult in resourceconstrained health systems. Screening in children has revealed low rates of colonisation. Active screening of paediatric patients found that 3.4% (41/1 211) were colonised with VRE, of whom 39/41 (95.1%) had an underlying chronic disease. [15] Risk factors for acquiring a BSI or colonisation with this highly resistant organism have been investigated. There are few paediatric studies regarding the risk factors for acquiring VRE. Acquisition of VRE has been associated with previous treatment with broad-spectrum antimicrobials, especially third-generation cepholosporins, and the carbapenems, as well as immunosuppression with antineoplastic chemotherapy, haemotology/oncology and renal patients, increased length of stay in hospital, and a younger age in children. [13] Progression from VRE colonisation to VRE-BSI in patients was associated with admission from a long-term care facility, infection of an additional body site other than blood and receipt of vancomycin. [16] In contrast, Pentima et al. [17] found that VRE-BSI was independent of patient vancomycin exposure. Risk factors in our patient cohort are similar to those described. All the patients with VRE-BSI had an underlying haematological condition requiring immunosuppressive therapy for treatment and received vancomycin for treating presumed Gram-positive infections. Central venous catheters were present in all four infected patients and, although not found to be a risk factor in the studies mentioned, could represent a possible clinical source for BSI. The colonised patients, although not clinically ill at the time, also had similar risk factors: all were exposed to vancomycin at some period during their illness and had underlying immunosuppression in the period preceding the screening. As mentioned, only one of the colonised patients progressed to developing bacteraemia with VRE.
Treatment for this resistant organism is limited to the use of linezolid and daptomycin. In SA, daptomycin is difficult to access in the public health system. Linezolid, an oxazolidinone antibacterial agent, has proven to be effective in the treatment of the glycopeptideresistant Enterococcus, as well as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae in children, and was used to treat the infected patients in this study. [18] 
Study limitations
The limitations of this study include lack of a case-control group to conclusively identify risk factors associated with VRE acquisition in our patients, and an insufficient sample size to ascertain whether an outbreak had occurred and to determine the definitive phylogenetic relationships of the VRE strains present in this setting. Owing to financial constraints, no active surveillance was possible after October 2013, so whether or not further transmission occurred and the duration of colonisation with VRE were not established. However, no further VRE cases were reported in the oncology unit or the hospital after November 2013.
Conclusion
In conclusion, effective infection control practices are important to limit or prevent transmission of multidrug-resistant pathogens among vulnerable hospitalised populations. Furthermore, the emergence of glycopeptide-resistant enterococci has emphasised the importance of antibiotic stewardship in the haematology/oncology unit and the institution overall. 
